10-K: Talphera Faces Going Concern Doubt Amidst Niyad Focus

Talphera, Inc. reported a net loss of $14.3 million for 2025, raising substantial doubt about its ability to continue as a going concern, despite focusing resources on its lead product candidate, Niyad.

Summary

• The company is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for use in medically supervised settings.
• Its primary product development focus is Niyad (nafamostat mesylate), a regional anticoagulant for use during continuous renal replacement therapy (CRRT), which has received Investigational Device Exemption (IDE) and Breakthrough Device Designation from the FDA.
• The registrational trial for Niyad (NEPHRO CRRT Study) is ongoing, with completion expected in 2026.
• The company is also evaluating LTX-608, a nafamostat formulation for direct IV infusion, for indications such as disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), or acute pancreatitis.
• Pre-filled syringe (PFS) product candidates (Fedsyra and Phenylephrine) are being evaluated for discontinuation due to the competitive market.
• The DSUVIA product was divested to Alora Pharmaceuticals, LLC in April 2023; however, Alora discontinued non-DoD sales in October 2024 and requested FDA withdrawal of the DSUVIA NDA in 2025, leading to the expected destruction of remaining inventory.
• The company incurred a net loss of $14.3 million in 2025, compared to $13.0 million in 2024, and has an accumulated deficit of $471.5 million as of December 31, 2025.
• Cash, cash equivalents, and short-term investments totaled $20.4 million as of December 31, 2025, up from $8.9 million as of December 31, 2024, primarily due to capital raises.
• Management has expressed substantial doubt about the company's ability to continue as a going concern, indicating a need for additional capital within the next twelve months.
• The company received a notice from Nasdaq on March 11, 2026, for non-compliance with the minimum bid price rule ($1.00 for 30 consecutive business days) and has until September 7, 2026, to regain compliance.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a highly concerning report due to the explicit 'going concern' doubt, continued net losses, and the effective termination of the DSUVIA product line. While Niyad shows promise with Breakthrough Device Designation and ongoing trials, the slow enrollment and the need for substantial additional capital present significant hurdles.

Positives

• Niyad has received Investigational Device Exemption (IDE) and Breakthrough Device Designation from the FDA, potentially expediting its development and review.
• The registrational trial for Niyad (NEPHRO CRRT Study) is ongoing, with completion expected in 2026, marking progress towards potential FDA approval.
• Niyad has the potential for six years of data exclusivity upon FDA approval, offering a period of market protection.
• The company estimates Niyad's peak sales potential may exceed $200 million annually in the United States if approved for use during CRRT and IHD.
• Successful capital raises through private placements in April and September 2025, and the monetization of DSUVIA payments in January 2024, increased cash, cash equivalents, and short-term investments to $20.4 million by December 31, 2025.
• The Ninth Circuit affirmed the District Court's dismissal of the securities class action on August 20, 2025, and related derivative actions were subsequently dismissed, resolving significant legal overhangs.
• The third closing of the April 2025 Private Placement occurred on March 13, 2026, following the announcement of 35 patient enrollments in the Niyad NEPHRO CRRT study and achievement of a target price milestone, providing an additional $4.1 million in gross proceeds.

Negatives

• There is substantial doubt regarding the company's ability to continue as a going concern, necessitating additional capital within the next twelve months.
• The company incurred significant net losses of $14.3 million in 2025 and has an accumulated deficit of $471.5 million as of December 31, 2025.
• Operating activities generated negative cash flows, indicating ongoing cash burn.
• Alora Pharmaceuticals, LLC discontinued DSUVIA sales efforts to non-DoD customers in October 2024 and requested FDA withdrawal of the DSUVIA NDA in 2025, leading to the expected destruction of remaining inventory and cessation of related payments.
• Efforts to facilitate a longer-term supply arrangement for DSUVIA were unsuccessful, and no prospective parties are currently interested in producing it.
• The NEPHRO CRRT clinical trial has experienced slower than expected site initiation and patient enrollment.
• The company received a Nasdaq notice on March 11, 2026, for non-compliance with the minimum bid price rule, risking delisting if compliance is not regained by September 7, 2026.
• An ownership change on September 10, 2025, triggered limitations on federal and state net operating loss carryforwards and research credits, resulting in the expiration of approximately $102.2 million in federal NOLs, $119.6 million in California NOLs, and $7.5 million in federal R&D credits.
• The XOMA Purchase Agreement is now estimated to result in future payments less than the proceeds received, deferring recognition of any probable contingent gain and indicating a less favorable outcome than initially projected.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern, requiring additional capital that may not be available.
• The company may be unable to maintain its listing on the Nasdaq exchange due to non-compliance with the minimum bid price rule.
• Failure to realize the expected benefits from the acquisition of Lowell Therapeutics, Inc. could adversely affect the stock price.
• Delays in clinical trials, such as the NEPHRO CRRT study's slower than expected enrollment, are common and could increase costs or jeopardize regulatory approval.
• Clinical trials of product candidates may fail to demonstrate safety and efficacy, leading to additional costs, delays, or inability to complete development.
• Difficulties in enrolling patients in clinical trials could delay or prevent necessary regulatory approvals.
• Identification of serious adverse effects or unexpected characteristics of product candidates during development may force abandonment or limitation of development.
• Limited resources may be expended on less profitable or less successful product candidates or indications.
• The process for obtaining Premarket Approval (PMA) or New Drug Application (NDA) is time-consuming, subject to unanticipated delays and costs, and requires substantial resources.
• Expectations for FDA approvability of product candidates may be inaccurate, requiring additional development work.
• Inability to compete effectively with other pharmaceutical and medical device companies could prevent products from reaching commercial potential.
• Coverage and adequate reimbursement may not be available for product candidates if approved, making profitable sales difficult.
• FDA and other regulatory agencies actively enforce laws prohibiting the promotion of off-label uses, potentially leading to significant liability.
• Inability to establish and maintain relationships with group purchasing organizations (GPOs) could jeopardize future revenues.
• Existing and future legislation, including healthcare reform measures, may increase the difficulty and cost of commercializing products and affect prices.
• Reliance on third-party manufacturers and single sources of supply for active ingredients and finished products (e.g., nafamostat from Asia) poses significant supply chain risks.
• Manufacturing issues could arise, delaying product development and regulatory approval or increasing costs.
• Reliance on third parties to conduct, supervise, and monitor clinical trials introduces risks if these parties perform unsatisfactorily.
• Relationships with healthcare professionals and partners are subject to anti-kickback, fraud, and abuse laws, potentially exposing the company to significant penalties.
• Significant disruptions of information technology systems or data security incidents could result in financial, legal, regulatory, business, and reputational harm.
• Business interruptions due to natural disasters, pandemics, or man-made incidents could delay operations and sales efforts.
• Future success depends on the ability to retain key executives and attract, retain, and motivate qualified personnel.
• Litigation involving patents, patent applications, and other proprietary rights is expensive and time-consuming.
• Inability to enforce intellectual property rights throughout the world, particularly in countries with less robust legal systems.
• The market price of common stock has historically been and may continue to be highly volatile.
• Sales of a substantial number of shares of common stock in the public market could cause the stock price to fall.
• Provisions in charter documents and Delaware law could make it more difficult or costly for a third party to acquire the company.
• Macroeconomic uncertainties, including inflationary pressures, supply chain disruptions, labor shortages, and recession risks, may adversely affect business and financial condition.
• International trade policies, including tariffs, sanctions, and trade barriers, may adversely affect business, especially given reliance on foreign suppliers.
• Ability to use net operating loss carryforwards and certain other tax attributes may be limited due to ownership changes.

Future Outlook

The company expects to continue incurring significant losses and negative cash flows from operations in 2026 and the foreseeable future, necessitating additional capital to fund planned operations beyond the next twelve months. The registrational trial for Niyad is expected to complete in 2026, after which a Premarket Approval (PMA) application will be submitted to the FDA. The company will evaluate the initial indication for LTX-608, potentially focusing on DIC or acute pancreatitis, and is assessing its strategy for Niyad's potential launch. The remaining DSUVIA inventory is expected to be destroyed if no DoD orders are secured. The company anticipates ongoing legislative and regulatory changes in healthcare that could impact product pricing and reimbursement.

Management Comments

• Management expects to need additional capital to fund its planned operations prior to the 12-month anniversary of the date this Annual Report on Form 10-K is filed with the United States Securities and Exchange Commission, or the SEC.
• While management believes its plans to raise additional funds will alleviate the conditions that raise substantial doubt about the Company's ability to continue as a going concern, these plans are not entirely within the Company's control and cannot be assessed as being probable of occurring.
• We are currently evaluating whether to discontinue our agreement with Aguettant given the other FDA approved pre-filled syringe products on the market and the principal focus of our resources on our nafamostat product candidates.

Industry Context

StockSavvy.ai notes that Talphera operates in a highly competitive and cost-pressured biotechnology and pharmaceutical industry. The company's focus on Niyad for CRRT, a market with no FDA-approved regional anticoagulant, presents a significant opportunity if successful. However, the broader trend of healthcare cost containment and increasing regulatory scrutiny, as evidenced by the One Big Beautiful Bill Act and discussions around Most-Favored Nation pricing, poses challenges for new product commercialization and profitability. The DSUVIA divestment and subsequent withdrawal request by Alora highlight the difficulties in commercializing products in competitive and regulated markets, especially for opioid-related therapies.

Comparison to Industry Standards

• Nafamostat, the active drug component of Niyad, has been approved and used in Japan and South Korea for over 30 years as a regional anticoagulant for dialysis, disseminated intravascular coagulation, and acute pancreatitis. This extensive international use provides a historical safety and efficacy profile that could potentially support Niyad's development efforts in the United States.
• For its pre-filled syringe (PFS) product candidates, the company notes the existence of 'at least two FDA-approved pre-filled ephedrine syringe products available on the market.' This indicates a competitive landscape where other companies have already achieved regulatory milestones for similar products, influencing Talphera's decision to potentially discontinue its PFS program.

Corporate Governance

Legal Proceedings

• A securities class action complaint filed on June 8, 2021, alleging violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 related to DSUVIA marketing, was dismissed with prejudice on May 7, 2024, and the dismissal was affirmed by the Ninth Circuit on August 20, 2025.
• Multiple shareholder derivative complaints filed between July and November 2021, based on the same alleged misstatements as the securities class action, were consolidated, stayed, and subsequently terminated on September 30, 2025, following the Ninth Circuit's order.
• Another shareholder derivative complaint filed in Delaware on February 16, 2024, asserting similar claims, was stayed and later dismissed on October 8, 2025.

Related Party Transactions

• A member of management participated in the April 2025 Private Placement.
• CorMedix Inc., a publicly traded life science company, participated in the September 2025 Private Placement and gained the right to designate a board member and a Right of First Negotiation for an Acquisition Transaction.

Stakeholder Impact

• **Shareholders:** Face significant risk of dilution from future equity offerings and potential delisting from Nasdaq, which could severely impact share price and liquidity. The 'going concern' doubt raises fundamental questions about the long-term viability of their investment.
• **Employees:** Potential for workforce reductions if additional capital is not secured. The company offers stock options and restricted stock units to foster ownership, but the overall financial uncertainty could impact morale and retention.
• **Customers (future):** If Niyad is successfully developed and approved, it could address an unmet medical need for a regional anticoagulant in CRRT, offering a new treatment option for patients.
• **Creditors:** The 'going concern' warning and reliance on future capital raises increase the risk profile for current and potential creditors.
• **Suppliers/Partners:** The company's reliance on single-source manufacturers for Niyad's active ingredient and finished product, particularly those located in Asia, exposes them to supply chain risks. The termination of DSUVIA-related agreements with Alora impacts previous partnership arrangements.

Next Steps

• Complete the Niyad NEPHRO CRRT study, with completion expected in 2026.
• Submit an application for Premarket Approval (PMA) to the FDA for Niyad upon completion of the trial.
• Evaluate the initial indication for LTX-608 and submit an Investigational New Drug (IND) application following toxicology evaluation to enable Phase 2 study.
• Evaluate whether to discontinue the agreement with Aguettant for pre-filled syringe (PFS) product candidates.
• Seek additional capital through public or private equity offerings, debt securities, a new debt facility, asset monetization, or licensing agreements.
• Address Nasdaq minimum bid price non-compliance by September 7, 2026, potentially through a reverse stock split.
• CorMedix has a Right of First Negotiation for an Acquisition Transaction following the public announcement of Niyad's primary endpoint achievement and topline clinical data.

Key Dates

Recommendation

The explicit 'substantial doubt' about the company's ability to continue as a going concern, coupled with persistent net losses, negative operating cash flow, and the complete failure of the DSUVIA product line, indicates severe financial distress. While Niyad has Breakthrough Device Designation, its slow trial enrollment and the company's precarious financial position make its successful commercialization highly uncertain. The Nasdaq delisting notice adds further pressure and risk to shareholders. Investors face substantial risk of capital loss and should consider exiting their positions.

Keywords

Talphera, TLPH, SEC filing, 10-K, annual report, pharmaceutical, medical device, Niyad, nafamostat, CRRT, regional anticoagulant, acute kidney injury, LTX-608, DIC, ARDS, acute pancreatitis, pre-filled syringe, DSUVIA, Alora, XOMA, capital raise, going concern, Nasdaq listing, clinical trials, FDA approval, intellectual property, corporate governance, financial results